Authors: A. Kapinová 1; I. Kašubová 1; M. Šarlinová 1; A. Mazuráková 2; D. Dvorská 1; D. Braný 1; Z. Danková 1,3; K. Kajo 4; P. Kubatka 5 Authors‘ workplace: Univerzita Komenského v Bratislave, Jesseniova lekárska fakulta v Martine, Martinské centrum pre biomedicínu, Martin, Slovenská republika 1; Univerzita Komenského v Bratislave, Jesseniova lekárska fakulta v Martine, Ústav anatómie, Martin, Slovenská republika 2; Univerzita Komenského v Bratislave, Jesseniova lekárska fakulta v Martine, Biobanka pre nádorové a zriedkavé ochorenia, Martin, Slovenská republika 3; Onkologický ústav sv. Alžbety, Ústav patológie, Bratislava, Slovenská republika 4; Univerzita Komenského v Bratislave, Jesseniova lekárska fakulta v Martine, Ústav lekárskej biológie, Martin, Slovenská republika 5 Published in: Klin Onkol 2025; 38(Supplementum 1): 104-107 Category: Article doi: https://doi.org/10.48095/ccko2024S104
Background: Whole plant foods are a rich source of a wide range of bioactive functional substances – phytochemicals, with extensive additive and/or synergistic effects within the process of carcinogenesis. Thanks to the growing body of evidence from preclinical studies on their effectiveness and relatively safe toxicological profile, they can be considered a suitable strategy in the prevention or adjuvant therapy of cancer diseases. Our study aimed to compare the antitumor capacity of various mixtures of phytochemicals contained in whole plant functional foods, namely in salvia (Salvia officinalis L.), aronia (Aronia melanocarpa L.), and sea buckthorn (Hippophae rhamnoides L.), in a chemopreventive model of breast cancer in female rats. Material and methods: Phytopharmaceuticals were administered to animals through the diet in three independent experiments using two concentrations: 1) a lower of 0.1% or 0.3% (Groups 0.1 or 0.3), and 2) a 10-fold higher of 1% or 3% (Groups 1 or 3). In the third group, serving as a control (CONT), no phytopharmaceuticals were administered to the animals. After completing each experiment, an analysis of the basic parameters of experimental mammary carcinogenesis and a comprehensive evaluation of well-validated prognostic, predictive, and diagnostic biomarkers used in oncological practice and preclinical research were performed. CS/LC-MS or LC-DAD/MS analysis of phytopharmaceuticals was performed to detect the presence of dominant phytochemicals. Results: A comprehensive analysis of the mechanism of action of plant-based functional foods confirmed their significant antitumor effects in our experimental breast cancer model, which were, however, specific to the phytopharmaceutical used. Phytopharmaceuticals significantly improved parameters of mammary carcinogenesis in vivo – incidence, frequency, latency of tumors, and/or ratio of HG/LG carcinomas. They statistically significantly improved the expression of markers of apoptosis, proliferation, angiogenesis, cancer stem cells, and oncogenic/tumor-suppressor miRNAs. In addition, chemoprevention led to significant modulation of histone chemical modifications and a decrease in methylation of promoter regions of tumor-suppressor genes. Conclusion: By comparing the efficacy of phytopharmaceuticals, we concluded that the presence of specific dominant plant metabolites may favorably influence the prognosis of mammary carcinogenesis. However, further preclinical and clinical research is necessary to confirm these findings, including assessing the potential of these agents as adjuvant therapy alongside standard oncological treatment.
breast cancer – Epigenetics – chemoprevention – phytopharmaceutical
1. Kim J, Harper A, McCormack V et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med 2025; 31 (4): 1154–1162. doi: 10.1038/s41591-025-03502-3.
2. Romanos-Nanclares A, Willett WC, Rosner BA et al. Healthful and unhealthful plant-based diets and risk of breast cancer in U.S. women: results from the Nurses’ Health Studies. Cancer Epidemiol Biomarkers Prev 2021; 30 (10): 1921–1931. doi: 10.1158/1055-9965.EPI-21-0352.
3. Fernández-Fígares Jiménez MDC. Role of a whole plant foods diet in breast cancer prevention and survival. [In press]. doi: 10.1080/27697061.2024.2442631.
4. Molina-Montes E, Salamanca-Fernández E, Garcia-Villanova B et al. The impact of plant-based dietary patterns on cancer-related outcomes: a rapid review and meta-analysis. Nutrients 2020; 12 (7): 2010. doi: 10.3390/nu12072010.
5. Bahrami H. Nutrition for cancer prevention and control: a review of dietary risk factors and protective measures. Cancer Screening and Prevention 2023; 2 (4): 250–259. doi: 10.14218/CSP.2023.00008S.
6. Kubatka P, Kapinová A, Kružliak P et al. Antineoplastic effects of Chlorella pyrenoidosa in the breast cancer model. Nutrition 2015; 31 (4): 560–569. doi: 10.1016/j.nut.2014.08.010.
7. Kubatka P, Kapinová A, Kello M et al. Fruit peel polyphenols demonstrate substantial anti-tumour effects in the model of breast cancer. Eur J Nutr 2016; 55 (3): 955–65. doi: 10.1007/s00394-015-0910-5.
8. Kubatka P, Uramova S, Kello M et al. Anticancer activities of Thymus vulgaris L. in experimental breast carcinoma in vivo and in vitro. Int J Mol Sci 2019; 20 (7): 1749. doi: 10.3390/ijms20071749.
9. Kubatka P, Kello M, Kajo K et al. Chemopreventive and therapeutic efficacy of Cinnamomum zeylanicum L. bark in experimental breast carcinoma: mechanistic in vivo and in vitro analyses. Molecules 2020; 25 (6): 1399. doi: 10.3390/molecules25061399.
10. Kubatka P, Mazurakova A, Koklesova L et al. Salvia officinalis L. exerts oncostatic effects in rodent and in vitro models of breast carcinoma. Front Pharmacol 2024a; 15 : 1216199. doi: 10.3389/fphar.2024.1216199.
11. Dvorska D, Mazurakova A, Lackova L et al. Aronia melanocarpa L. fruit peels show anti-cancer effects in preclinical models of breast carcinoma: the perspectives in the chemoprevention and therapy modulation. Front Oncol 2024b; 14 : 1463656. doi: 10.3389/fonc.2024. 1463656.
12. Dvorska D, Sebova D, Kajo K et al. Chemopreventive and therapeutic effects of Hippophae rhamnoides L. fruit peels evaluated in preclinical models of breast carcinoma. Front Pharmacol 2025; 16 : 1561436. doi: 10.3389/fphar.2025.1561436.
13. Krystel-Whittemore M, Tan PH, Wen HY. Predictive and prognostic biomarkers in breast tumours. Pathology 2024; 56 (2): 186–191. doi: 10.1016/j.pathol.2023.10.014.
14. Tarighati E, Keivan H, Mahani H. A review of prognostic and predictive biomarkers in breast cancer. Clin Exp Med 2023; 23 (1): 1–16. doi: 10.1007/s10238-021-00781-1.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
